西格列他钠与吡格列酮治疗2型糖尿病疗效比较

Efficacy Comparison of Siglietazide Sodium and Pioglitazone in the Treatment of Type 2 Diabetes Mellitus

目的比较西格列他钠和吡格列酮治疗2型糖尿病的临床疗效,以及对患者糖脂代谢的影响。方法选取医院2022年8月至2023年4月收治的2型糖尿病患者50例,按奇偶数法分为对照组和观察组,各50例。对照组患者予吡格列酮,观察组患者予西格列他钠,比较两组的临床疗效及糖脂代谢情况。结果观察组患者的血糖指标、胰岛功能指标、血脂指标较对照组改善更显著(P<0.05);观察组治疗期间的药品不良反应发生率显著低于对照组(P<0.05);观察组患者的糖尿病并发症发生率显著低于对照组(P<0.05)。结论西格列他钠治疗2型糖尿病的临床疗效优于吡格列酮,且对患者机体糖脂代谢水平的调节更有效,且安全性更高。

Objective To compare the clinical efficacy of pioglitazone and sitaglipta sodium in the treatment of type 2 diabetes mellitus(T2DM),and their effects on glucose and lipid metabolism.Methods A total of 50 patients with T2DM admitted to the hospital from August 2022 to April 2023 were selected and divided into the control group and the observation group according to the odd even number method,with 50 cases in each group.The control group was given pioglitazone,while the observation group was given sitagliptat sodium.The clinical efficacy and glucose and lipid metabolism in the two groups were compared.Results The blood glucose indicators,pancreatic islet function indicators,and blood lipid indicators in the observation group was significant better than those in the control group(P<0.05).The incidence of adverse drug reactions during treatment in the observation group was significantly lower than that in the control group(P<0.05).The incidence of complications of diabetes in the observation group was significantly lower than that in the control group(P<0.05).Conclusion Sitaglipta sodium in the treatment of T2DM has better efficacy than pioglitazone,and it is more effective in regulating the level of glucose and lipid metabolism in patients with higher safety.